Fundz

ImmunityBio

San Diego, CA · Biotechnology · 35 employees

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

Funding history

  • Funding Round — $80.0M — Jul 2025
  • Funding Round — $320.0M — Jan 2024
  • Funding Round — $470.0M — Sep 2023
  • Funding Round — $470.0M — Sep 2023
  • Funding Round — $157.0M — Dec 2022

Recent signals

  • May 16, 2026: ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for Tokyo Strain of BCG to Improve Supply in the U.S.
  • Dec 23, 2025: SEC 8-K (1.01): On December 23, 2025, ImmunityBio, Inc. entered into Amendment No. 1 to the Open Market Sale Agreement regarding the sale and issuance of its common stock through an ‘at the market’ offering program, with Jefferies LLC acting as the sales agent. This amendment permits the issuance of an additional $459,972,480 of common shares, which are registered under a newly filed prospectus supplement on the same date. This increase in share issuance capacity is expected to enhance the Company's financial flexibility in capital raising efforts.
  • Dec 10, 2025: SEC 8-K (5.02): On December 10, 2025, ImmunityBio, Inc. appointed Bruce Wendel to its Board of Directors, with the appointment becoming effective on December 12, 2025. Mr. Wendel's term is set to expire at the company's 2026 annual meeting of stockholders. The Board has confirmed that he qualifies as an independent director according to Nasdaq and SEC standards. Prior to this appointment, Mr. Wendel held significant positions including Chief Business Development Officer at ProMetic Biosciences Ltd. from April 2018 to May 2019, thus bringing valuable experience to the Board.
  • Jul 25, 2025: Raised $80.0M
  • Jan 15, 2025: Launched ImmunityBio, Inc. announces regulatory submission for ANKTIVA® plus BCG to treat bladder cancer in Europe and the UK.
  • Jan 02, 2024: Raised $320.0M
  • Sep 22, 2023: Raised $470.0M
  • Sep 11, 2023: Raised $470.0M

See plans & pricing → Track ImmunityBio’s funding, hiring, and signals — with verified contacts — on Fundz.